Leerink Partners analyst Andrew Berens reiterated a Hold rating on Exelixis (EXEL – Research Report) on February 11 and set a price target of $32.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Andrew Berens has given his Hold rating due to a combination of factors related to Exelixis’s current financial and strategic positioning. The company’s fourth-quarter results for 2024 were generally as expected, with slight improvements in net product and total revenue, but these outcomes had been largely anticipated due to preannouncements. While the financial guidance for 2025 was reiterated, indicating stability, there was no significant new information to suggest a change in the company’s growth trajectory.
Key strategic priorities and upcoming milestones remain unchanged, with a focus on pivotal trial data for their product, Zanza, expected in the second half of 2025. However, the lack of additional clarity on potential regulatory filings for other products and ongoing reviews suggests a cautious outlook. Management’s confidence in product launches and trial outcomes is noted, but until more definitive results and regulatory approvals are secured, the Hold rating reflects a wait-and-see approach to Exelixis’s future performance.
In another report released yesterday, Stifel Nicolaus also maintained a Hold rating on the stock with a $36.00 price target.
Based on the recent corporate insider activity of 79 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EXEL in relation to earlier this year.